Hypertension Treatment with Losartan and Candesartan

Patient Selection and Treatment Outcomes

• For hypertensive patients with left ventricular hypertrophy, the European Society of Cardiology recommends losartan, which has demonstrated superior outcomes compared to atenolol in reducing cardiovascular events, particularly stroke (25% reduction) 1, 2
• The American Heart Association suggests that candesartan also showed significant stroke reduction (40-42%) in elderly patients with isolated systolic hypertension 1, 2

Dosing Considerations

• The European Society of Cardiology recommends optimal losartan dosing for cardiovascular protection requires 100-150 mg daily, substantially higher than typical hypertension dosing 4, 5
• The American College of Cardiology suggests that candesartan's standard hypertension dose of 16-32 mg daily aligns with doses proven effective in cardiovascular outcome trials 4, 5

Combination Therapy and Monitoring

• The European Society of Cardiology recommends that neither losartan nor candesartan should be combined with ACE inhibitors or direct renin inhibitors due to increased adverse events without additional benefit 2, 6
• The American Heart Association suggests monitoring renal function and potassium levels at baseline and 2-4 weeks after initiation, and targeting blood pressure <130/80 mmHg for patients with diabetes or chronic kidney disease 6, 7